Рецепт. 2018; : 379-391
Гиперкортизолизм, или болезнь Кушинга: меняются ли диагностические и лечебные подходы?
Аннотация
Сложности в верификации генеза гиперкортизолизма по-прежнему имеют место, что определяет внесение изменений и дополнений в международные рекомендации по диагностике и лечению синдрома или болезни Кушинга. За последнее десятилетие изменились подходы к употреблению ряда терминов, были пересмотрены диагностические тесты, расширился спектр лекарственных средств.
Список литературы
1. Boscaro M., Arnaldi G. (2009) Approach to the Patient with Possible Cushing Syndrome. J Clin Endocrinol Metab., vol. 94, pp. 3121-3131.
2. León-Justel A., Madrazo-Atutxa A., Alvarez-Rios A.I., Infantes-Fontán R., Garcia-Arnés J.A. (2016) A Probabilistic Model for Cushing Syndrome Screening in At-Risk Populations: A Prospective Multicenter Study. J Clin Endocrinol Metab., vol. 101 (10), pp. 3747-3754.
3. Biller B.M.K., Grossman A.B., Stewart P.M., Melmed S., Bertagna X., Bertherat J., Buchfelder M., Colao A., Hermus A.R., Hofland L.J., Klibanski A., Lacroix A., Lindsay J.R., Newell-Price J., Nieman L.K., Petersenn S., Sonino N., Stalla G.K., Swearingen B., Vance M.L., Wass J.A.H., Boscaro M. (2008) Treatment of Adrenocorticotropin-Dependent Cushing Syndrome: A Consensus Statement. J Clin Endocrinol Metab., vol. 93 (7), pp. 2454-2462.
4. Danilova L. (2011) Mnozhestvennie endokrinnie neoplazii. Rukovodstvo po endokrinologii pod red. E. Holodovoi [Multiple endocrine neoplasia. Guideline on Endocrinology edited by E. Kholodova]. Moskva: «Meditsinskoe informatsionnoe agenstvo», VII, pp. 367-397.
5. Nieman L.K., Biller B.M.K., Findling J.W., J. Newell-Price, Savage M.O., Stewart P.M., Montori V.M. (2008) The diagnosis of Cushing Syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metabol., vol. 93, pp. 1526-1540.
6. Raff H., Auchus R.J., Findling J.W., Nieman L.K. (2015) Urine Free Cortisol in the Diagnosis of Cushing Syndrome: Is It Worth Doing and, If So, How? J Clin Endocrinol Metab, vol. 100 (2), pp. 395-397.
7. Arlt W., Biehl M., Taylor A.E., Hahner S., Libé R., Hughes B.A., Schneider P., Smith D.J., Stiekema H., Krone N., Porfiri E., Opocher G., Bertherat J., Mantero F., Allolio B., Terzolo M., Nightingale P., Shackleton C.H.L., Bertagna X., Fassnacht M., Stewart P.M. (2011) Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors. J Clin Endocrinol Metab., vol. 96, pp. 3775-3784.
8. Shi Chen, Ran Li, Xiaobo Zhang, Lin Lu, Ji Li (2018) Combined Ovarian and Adrenal Venous Sampling in the Localization of Adrenocorticotropic Hormone-Independent Ectopic Cushing Syndrome. J Clin Endocrinol Metab., vol. 103 (3), pp. 803-808.
9. Puar T., Manon Engels M., Antonius E. van Herwaarden, Fred C.G.J. Sweep, Christina Hulsbergen-van de Kaa (2017) Bilateral Testicular Tumors Resulting in Recurrent Cushing Disease After Bilateral Adrenalectomy. J Clin Endocrinol Metab., vol. 102 (2), pp. 339-344.
10. Roussel-Gervais A., Couture C., Langlais D., Takayasu S., Balsalobre A. (2016) The Cables1 Gene in Glucocorticoid Regulation of Pituitary Corticotrope Growth and Cushing Disease. J Clin Endocrinol Metab, vol. 101, pp. 513-522.
11. Manenschijn L., Koper J. W., van den Akker E.L.T., de Heide L.J.M., E. Geerdink E.A.M. (2012) A Novel Tool in the Diagnosis and Follow-Up of (Cyclic) Cushing Syndrome: Measurement of Long-Term Cortisol in Scalp Hair. J Clin Endocrinol Metab., vol. 97, pp. E1836-E1843.
12. Bushnell Jr D.L., O’Dorisio T.M., O’Dorisio M.S., Menda Y., Hicks R.J.,Van Cutsem E., Baulieu J.L., Borson-Chazot F., Anthony L., Benson A.B., Oberg K., Grossman A.B., Connolly M., Bouterfa H., Li Y., Kacena K.A., LaFrance N., Pauwels S.A. (2010) 90Y-Edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol., vol. 28, pp. 1652-1659.
13. Batista D.L., Oldfield E.H., Keil M.F., Stratakis C.A. (2009) Postoperative Testing to Predict Recurrent Cushing Disease in Children. J Clin Endocrinol Metab., vol. 94, pp. 2757-2765.
14. Carroll T., Raff H., Findling J.W. (2009) Late-night salivary cortisol for the diagnosis of Cushing syndrome: a meta- analysis. Endocr Pract., vol. 15 (4), pp. 335-342.
15. Crocker M.K., Barak S., Millo C.M., Beall S.A., Niyyati M., Chang R., Avila N.A., van Ryzin C., Segars J., Quezado M., Merke D.P. (2012) Use of PET/CT with Cosyntropin Stimulation to Identify and Localize Adrenal Rest Tissue following Adrenalectomy in a Woman with Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab., vol. 97, pp. E2084-E2089.
16. Heaney A.P. (2008) Pituitary Carcinoma: Difficult Diagnosis and Treatment. J Clin Endocrinol Metab., vol. 96, pp. 3649-3660.
17. Silye R., Rieger R., Topakian R., Dunzinger A., Aigner R.M., Pichler R. (2012) Image in Endocrinology: Cushing Syndrome due to Ectopic Adrenocorticotropin Secretion by Oncocytic Thyroid Nodule. J Clin Endocrinol Metab, vol. 97, pp. 39-40.
18. Terzolo M., Reimondo G., Chiodini I., Castello R., Giordano R. (2012) Screening of Cushing Syndrome in Outpatients with Type 2 Diabetes: Results of a Prospective Multicentric Study in Italy. J Clin Endocrinol Metab., vol. 97, pp. 3467-3475.
19. Cuevas-Ramos M., Fleseriu M. (2015) Treatment of Cushing’s disease: a mechanistic update. http://joe.endocrinology- journals.org, Society for Endocrinology doi: 10.1530/JOE-14-0300.
20. Daniel E., Aylwin S., Mustafa O., Ball S., Munir A., Boelaert K., Chortis V. (2015) Effectiveness of Metyrapone in Treating Cushing Syndrome: A Retrospective Multicenter Study in 195 Patients. J Clin Endocrinology Metabolism, vol. 100, pp. 4146-4154.
21. Bertagna X., Pivonello R., Fleseriu M., Zhang Y., Robinson P., Taylor A., Watson C.E., Maldonado M., Hamrahian A.H., Boscaro M., Biller B.M. (2014) LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing disease: results from a multicenter, proof-of- concept study. J Clin Endocrinol Metab, vol. 99, pp. 1375-1383.
22. Heyn J., Greiger C., Hinske C.L. (2012) Medical suppression of hypercortisolemia in Cushing syndrome with particular consideration of etomidate. Pituitary, vol. 15, pp. 117-125.
23. Castinetti F., Brue T., Conte-Devolx B. (2012)The use of the glucocorticoid receptor antagonist mifepristone in Cushing syndrome. Curr Opin Endocrinol Diabetes Obes, vol. 19, pp. 295-299.
24. Ferone D., Pivonello C., Vitale G., Zatelli M.C., Colao A., Pivonello R. (2013) Molecular basis of pharmacological therapy in Cushing disease. Endocrine, vol. 46, pp. 181-198.
25. Hur K., Kim J.K., Kim B. J., Kim M.-S., Lee E.J., Kim S.-W. (2015) Clinical Guidelines for the Diagnosis and Treatment of Cushing Disease in Korea. Endocrinol Metabol, vol. 3, pp. 7-18.
26. CeccatoF., Scaroni C., Boscaro M. (2015) Clinical use of pasireotide for Cushing disease in adults. Therapeutics and Clinical Risk Management, vol. 11, pp. 425-434.
27. Colao A., Petersenn S., Newell-Price J., Findling J.W., Gu F., Maldonado M., Schoenherr U., Mills D., Salgado L.R., Biller B.M. (2012) A 12-month phase 3 study of pasireotide in Cushing disease. NEJM, vol. 366, pp. 914-924.
28. Wang R., Yang Y., Sheng M., Dechao Bu, Huang H., Xiaohai Liu, Cuiqi Zhou, Congxin Dai, Sun B., Zhu J., Yi Qiao (2016) Phenotype-Genotype Association Analysis of ACTH-Secreting Pituitary Adenoma and Its Molecular Link to Patient Osteoporosis. Int. J. Mol. Sci., vol. 17, pp. 1654-1662.
29. Henry R., Mudaliar S., Hermosillo Rese'ndiz K., Ligueros-Saylan M., Chenji S., Golor G. (2011) Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers. Endocrine Reviews, vol. 32, pp. 3-274.
30. De Bruin C., Feelders R.A., Lamberts S.W., Hofland L.J. (2009) Somatostatin and dopamine receptors as targets for medical treatment of Cushing syndrome. Rev Endocrin Metabolic Disorders, vol. 10, pp. 91-102.
31. De Bruin C., Hofland L.J., Nieman L.K., van Koetsveld P.M. (2012) Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing syndrome due to ectopic adrenocorticotropin secretion. J Clin Endocrinology Metabolism, vol. 97, pp. 455-462.
32. Schmid H.A., BrueT., ColaoA., Gadelha M. R., Shimon I., Kapur K., Pedroncelli A.M., Fleseriu M. (2016) Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine, vol. 53, pp. 210-219.
33. Gadelha M.R., Bronstein M.D., Brue T. (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol., vol. 2, pp. 875-884.
34. Sheppard M., Bronstein M.D., Freda P., Serri O. (2015) Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double- blind, multicenter, Phase III study. Pituitary, vol. 18, pp. 385-394.
Recipe. 2018; : 379-391
Hypercorticoidism or Cushing Disease: are diagnostic and treatment approaches changing?
Abstract
References
1. Boscaro M., Arnaldi G. (2009) Approach to the Patient with Possible Cushing Syndrome. J Clin Endocrinol Metab., vol. 94, pp. 3121-3131.
2. León-Justel A., Madrazo-Atutxa A., Alvarez-Rios A.I., Infantes-Fontán R., Garcia-Arnés J.A. (2016) A Probabilistic Model for Cushing Syndrome Screening in At-Risk Populations: A Prospective Multicenter Study. J Clin Endocrinol Metab., vol. 101 (10), pp. 3747-3754.
3. Biller B.M.K., Grossman A.B., Stewart P.M., Melmed S., Bertagna X., Bertherat J., Buchfelder M., Colao A., Hermus A.R., Hofland L.J., Klibanski A., Lacroix A., Lindsay J.R., Newell-Price J., Nieman L.K., Petersenn S., Sonino N., Stalla G.K., Swearingen B., Vance M.L., Wass J.A.H., Boscaro M. (2008) Treatment of Adrenocorticotropin-Dependent Cushing Syndrome: A Consensus Statement. J Clin Endocrinol Metab., vol. 93 (7), pp. 2454-2462.
4. Danilova L. (2011) Mnozhestvennie endokrinnie neoplazii. Rukovodstvo po endokrinologii pod red. E. Holodovoi [Multiple endocrine neoplasia. Guideline on Endocrinology edited by E. Kholodova]. Moskva: «Meditsinskoe informatsionnoe agenstvo», VII, pp. 367-397.
5. Nieman L.K., Biller B.M.K., Findling J.W., J. Newell-Price, Savage M.O., Stewart P.M., Montori V.M. (2008) The diagnosis of Cushing Syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metabol., vol. 93, pp. 1526-1540.
6. Raff H., Auchus R.J., Findling J.W., Nieman L.K. (2015) Urine Free Cortisol in the Diagnosis of Cushing Syndrome: Is It Worth Doing and, If So, How? J Clin Endocrinol Metab, vol. 100 (2), pp. 395-397.
7. Arlt W., Biehl M., Taylor A.E., Hahner S., Libé R., Hughes B.A., Schneider P., Smith D.J., Stiekema H., Krone N., Porfiri E., Opocher G., Bertherat J., Mantero F., Allolio B., Terzolo M., Nightingale P., Shackleton C.H.L., Bertagna X., Fassnacht M., Stewart P.M. (2011) Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors. J Clin Endocrinol Metab., vol. 96, pp. 3775-3784.
8. Shi Chen, Ran Li, Xiaobo Zhang, Lin Lu, Ji Li (2018) Combined Ovarian and Adrenal Venous Sampling in the Localization of Adrenocorticotropic Hormone-Independent Ectopic Cushing Syndrome. J Clin Endocrinol Metab., vol. 103 (3), pp. 803-808.
9. Puar T., Manon Engels M., Antonius E. van Herwaarden, Fred C.G.J. Sweep, Christina Hulsbergen-van de Kaa (2017) Bilateral Testicular Tumors Resulting in Recurrent Cushing Disease After Bilateral Adrenalectomy. J Clin Endocrinol Metab., vol. 102 (2), pp. 339-344.
10. Roussel-Gervais A., Couture C., Langlais D., Takayasu S., Balsalobre A. (2016) The Cables1 Gene in Glucocorticoid Regulation of Pituitary Corticotrope Growth and Cushing Disease. J Clin Endocrinol Metab, vol. 101, pp. 513-522.
11. Manenschijn L., Koper J. W., van den Akker E.L.T., de Heide L.J.M., E. Geerdink E.A.M. (2012) A Novel Tool in the Diagnosis and Follow-Up of (Cyclic) Cushing Syndrome: Measurement of Long-Term Cortisol in Scalp Hair. J Clin Endocrinol Metab., vol. 97, pp. E1836-E1843.
12. Bushnell Jr D.L., O’Dorisio T.M., O’Dorisio M.S., Menda Y., Hicks R.J.,Van Cutsem E., Baulieu J.L., Borson-Chazot F., Anthony L., Benson A.B., Oberg K., Grossman A.B., Connolly M., Bouterfa H., Li Y., Kacena K.A., LaFrance N., Pauwels S.A. (2010) 90Y-Edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol., vol. 28, pp. 1652-1659.
13. Batista D.L., Oldfield E.H., Keil M.F., Stratakis C.A. (2009) Postoperative Testing to Predict Recurrent Cushing Disease in Children. J Clin Endocrinol Metab., vol. 94, pp. 2757-2765.
14. Carroll T., Raff H., Findling J.W. (2009) Late-night salivary cortisol for the diagnosis of Cushing syndrome: a meta- analysis. Endocr Pract., vol. 15 (4), pp. 335-342.
15. Crocker M.K., Barak S., Millo C.M., Beall S.A., Niyyati M., Chang R., Avila N.A., van Ryzin C., Segars J., Quezado M., Merke D.P. (2012) Use of PET/CT with Cosyntropin Stimulation to Identify and Localize Adrenal Rest Tissue following Adrenalectomy in a Woman with Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab., vol. 97, pp. E2084-E2089.
16. Heaney A.P. (2008) Pituitary Carcinoma: Difficult Diagnosis and Treatment. J Clin Endocrinol Metab., vol. 96, pp. 3649-3660.
17. Silye R., Rieger R., Topakian R., Dunzinger A., Aigner R.M., Pichler R. (2012) Image in Endocrinology: Cushing Syndrome due to Ectopic Adrenocorticotropin Secretion by Oncocytic Thyroid Nodule. J Clin Endocrinol Metab, vol. 97, pp. 39-40.
18. Terzolo M., Reimondo G., Chiodini I., Castello R., Giordano R. (2012) Screening of Cushing Syndrome in Outpatients with Type 2 Diabetes: Results of a Prospective Multicentric Study in Italy. J Clin Endocrinol Metab., vol. 97, pp. 3467-3475.
19. Cuevas-Ramos M., Fleseriu M. (2015) Treatment of Cushing’s disease: a mechanistic update. http://joe.endocrinology- journals.org, Society for Endocrinology doi: 10.1530/JOE-14-0300.
20. Daniel E., Aylwin S., Mustafa O., Ball S., Munir A., Boelaert K., Chortis V. (2015) Effectiveness of Metyrapone in Treating Cushing Syndrome: A Retrospective Multicenter Study in 195 Patients. J Clin Endocrinology Metabolism, vol. 100, pp. 4146-4154.
21. Bertagna X., Pivonello R., Fleseriu M., Zhang Y., Robinson P., Taylor A., Watson C.E., Maldonado M., Hamrahian A.H., Boscaro M., Biller B.M. (2014) LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing disease: results from a multicenter, proof-of- concept study. J Clin Endocrinol Metab, vol. 99, pp. 1375-1383.
22. Heyn J., Greiger C., Hinske C.L. (2012) Medical suppression of hypercortisolemia in Cushing syndrome with particular consideration of etomidate. Pituitary, vol. 15, pp. 117-125.
23. Castinetti F., Brue T., Conte-Devolx B. (2012)The use of the glucocorticoid receptor antagonist mifepristone in Cushing syndrome. Curr Opin Endocrinol Diabetes Obes, vol. 19, pp. 295-299.
24. Ferone D., Pivonello C., Vitale G., Zatelli M.C., Colao A., Pivonello R. (2013) Molecular basis of pharmacological therapy in Cushing disease. Endocrine, vol. 46, pp. 181-198.
25. Hur K., Kim J.K., Kim B. J., Kim M.-S., Lee E.J., Kim S.-W. (2015) Clinical Guidelines for the Diagnosis and Treatment of Cushing Disease in Korea. Endocrinol Metabol, vol. 3, pp. 7-18.
26. CeccatoF., Scaroni C., Boscaro M. (2015) Clinical use of pasireotide for Cushing disease in adults. Therapeutics and Clinical Risk Management, vol. 11, pp. 425-434.
27. Colao A., Petersenn S., Newell-Price J., Findling J.W., Gu F., Maldonado M., Schoenherr U., Mills D., Salgado L.R., Biller B.M. (2012) A 12-month phase 3 study of pasireotide in Cushing disease. NEJM, vol. 366, pp. 914-924.
28. Wang R., Yang Y., Sheng M., Dechao Bu, Huang H., Xiaohai Liu, Cuiqi Zhou, Congxin Dai, Sun B., Zhu J., Yi Qiao (2016) Phenotype-Genotype Association Analysis of ACTH-Secreting Pituitary Adenoma and Its Molecular Link to Patient Osteoporosis. Int. J. Mol. Sci., vol. 17, pp. 1654-1662.
29. Henry R., Mudaliar S., Hermosillo Rese'ndiz K., Ligueros-Saylan M., Chenji S., Golor G. (2011) Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers. Endocrine Reviews, vol. 32, pp. 3-274.
30. De Bruin C., Feelders R.A., Lamberts S.W., Hofland L.J. (2009) Somatostatin and dopamine receptors as targets for medical treatment of Cushing syndrome. Rev Endocrin Metabolic Disorders, vol. 10, pp. 91-102.
31. De Bruin C., Hofland L.J., Nieman L.K., van Koetsveld P.M. (2012) Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing syndrome due to ectopic adrenocorticotropin secretion. J Clin Endocrinology Metabolism, vol. 97, pp. 455-462.
32. Schmid H.A., BrueT., ColaoA., Gadelha M. R., Shimon I., Kapur K., Pedroncelli A.M., Fleseriu M. (2016) Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine, vol. 53, pp. 210-219.
33. Gadelha M.R., Bronstein M.D., Brue T. (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol., vol. 2, pp. 875-884.
34. Sheppard M., Bronstein M.D., Freda P., Serri O. (2015) Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double- blind, multicenter, Phase III study. Pituitary, vol. 18, pp. 385-394.
